Artiva Biotherapeutics, Inc.
Nasdaq · Healthcare · Biological Products, (No Diagnostic Substances) · San Diego, CA
ARTV chart
What traders are saying about $ARTV
Latest postsArtiva Biotherapeutics, Inc. news
- Pemphigus Vulgaris Market and Pipeline Appear Promising With Key Pharma Companies Actively Working in the Therapeutics Segment | DelveInsight
StreetInsider ·
- Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation int
The National Law Review ·
- Artiva Biotherapeutics discontinues AlloNK development
The Pharma Letter ·
- Artiva Biotherapeutics CEO Fred Aslan Executes Automatic Sale of 62,178 Shares for Tax Withholding
Kalkine Media ·
- Artiva Biotherapeutics CMO Subhashis Banerjee Sells 1,110 Shares to Cover RSU Tax Withholding
Kalkine Media ·
- Sector Update: Healthcare Stocks Decline Late Afternoon
Yahoo Finance ·
- Artiva Biotherapeutics Plunges Into Crisis Over Patient Deaths and Possible Liquidation
Yahoo Finance ·
- Why Is Artiva Biotherapeutics Discontinuing AlloNK Development and Cutting 94% of Its Workforce?
investorshub.advfn.com ·
- Artiva to quit autoimmune cell therapy work, cut staff after patient deaths
biopharmadive.com ·
- Artiva Scraps Development Of Lead Drug Candidate After Patient Deaths — ARTV Stock Heads For Worst Session In Over 18 Months
stocktwits.com ·
- Artiva Biotherapeutics stock tumbles after halting drug trial
Yahoo Finance ·
- Artiva Biotherapeutics Announces Strategic Update and Discontinues Development of AlloNK®
Yahoo Finance ·
Artiva Biotherapeutics, Inc. key financials
| USD | 2025 | 2024 | 2023 |
|---|---|---|---|
| Revenue | $0 | $251,000 | $33.5M |
| Net income | -$83.9M | -$65.4M | -$28.7M |
| Diluted EPS | $-3.43 | $-5.81 | $-35.78 |
| Total assets (year end) | $130.9M | $209.6M | $105.1M |
| Cash and equivalents (year end) | $26.7M | $40.2M | $53.5M |
Calendar-year figures as reported to the SEC in XBRL filings.
Recent SEC filings
About Artiva Biotherapeutics, Inc.
- Ticker
- ARTV (Nasdaq)
- Industry
- Biological Products, (No Diagnostic Substances)
- Headquarters
- San Diego, CA
- Incorporated in
- DE
- Fiscal year end
- December 31
- SEC CIK
- 1817241
Frequently asked questions
What exchange is Artiva Biotherapeutics, Inc. listed on?
Artiva Biotherapeutics, Inc. trades on the Nasdaq under the ticker symbol ARTV.
What industry is Artiva Biotherapeutics, Inc. in?
Artiva Biotherapeutics, Inc. is classified by the SEC under "Biological Products, (No Diagnostic Substances)", part of the Healthcare sector on StockTweeting.
Where is Artiva Biotherapeutics, Inc. headquartered?
Artiva Biotherapeutics, Inc.'s business address on file with the SEC is in San Diego, CA.
When does Artiva Biotherapeutics, Inc.'s fiscal year end?
Artiva Biotherapeutics, Inc.'s fiscal year ends on December 31.
How much revenue did Artiva Biotherapeutics, Inc. report?
Artiva Biotherapeutics, Inc. reported $0 in revenue for calendar year 2025, according to its SEC filings.